MDxHealth SA (NASDAQ:MDXH - Get Free Report) was the target of a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 56,300 shares, an increase of 81.0% from the February 28th total of 31,100 shares. Currently, 0.3% of the shares of the company are sold short. Based on an average trading volume of 104,100 shares, the short-interest ratio is presently 0.5 days.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the stock. Samjo Management LLC grew its stake in shares of MDxHealth by 130.9% during the 4th quarter. Samjo Management LLC now owns 1,824,312 shares of the company's stock worth $4,324,000 after purchasing an additional 1,034,312 shares during the period. AWM Investment Company Inc. boosted its holdings in MDxHealth by 11.1% during the fourth quarter. AWM Investment Company Inc. now owns 4,721,290 shares of the company's stock worth $11,189,000 after buying an additional 471,290 shares in the last quarter. Northern Trust Corp purchased a new stake in MDxHealth during the fourth quarter worth $1,033,000. Perkins Capital Management Inc. grew its position in MDxHealth by 31.6% during the fourth quarter. Perkins Capital Management Inc. now owns 983,475 shares of the company's stock valued at $2,331,000 after buying an additional 236,100 shares during the period. Finally, Renaissance Technologies LLC increased its holdings in MDxHealth by 715.2% in the fourth quarter. Renaissance Technologies LLC now owns 123,100 shares of the company's stock valued at $292,000 after buying an additional 108,000 shares in the last quarter.
MDxHealth Stock Performance
Shares of NASDAQ:MDXH traded up $0.05 during midday trading on Wednesday, reaching $1.50. The company's stock had a trading volume of 66,521 shares, compared to its average volume of 84,320. The company has a quick ratio of 1.45, a current ratio of 1.54 and a debt-to-equity ratio of 3.14. The stock has a fifty day moving average of $1.73 and a 200 day moving average of $1.97. MDxHealth has a twelve month low of $1.35 and a twelve month high of $3.50. The firm has a market capitalization of $70.93 million, a PE ratio of -0.99 and a beta of 1.37.
MDxHealth (NASDAQ:MDXH - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.07. The company had revenue of $24.74 million for the quarter, compared to the consensus estimate of $22.67 million. MDxHealth had a negative return on equity of 1,077.84% and a negative net margin of 49.52%. On average, equities analysts expect that MDxHealth will post -1.15 EPS for the current fiscal year.
MDxHealth Company Profile
(
Get Free Report)
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.
Read More
Before you consider MDxHealth, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MDxHealth wasn't on the list.
While MDxHealth currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.